Prelude Therapeutics Incorporated (PRLD) Stock Price

PRLDStock

$6.59+421.77%52W

Market Cap$525.90M

P/E—

PEG Ratio—

Div yield—

Beta0.93

PRLD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)189.68%

Price vs S&P 500 (4W)36.39%

VGM Score65.47

Book Value / Share (Quarterly)$0.95

P/TBV (Annual)0.93x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.69

Price vs S&P 500 (YTD)111.14%

Net Profit Margin (TTM)-278.51%

EPS (TTM)$-0.59

10-Day Avg Trading Volume0.71M

EPS Excl Extra (TTM)$-0.59

EPS (Annual)$-1.29

ROI (Annual)-144.96%

Cash / Share (Quarterly)$1.29

Revenue Growth QoQ (YoY)41.00%

ROA (Last FY)-70.41%

EBITD / Share (TTM)$-0.64

ROE (5Y Avg)-78.25%

Operating Margin (TTM)-310.66%

Cash Flow / Share (Annual)$-0.90

P/B Ratio7.17x

P/B Ratio (Quarterly)3.58x

Net Income / Employee (Annual)$-1,259,500

EV / Revenue (TTM)24.52x

ROA (TTM)-39.27%

EPS Incl Extra (Annual)$-1.29

Current Ratio (Annual)1.99x

Quick Ratio (Quarterly)1.95x

3-Month Avg Trading Volume0.48M

52-Week Price Return421.77%

Revenue / Employee (TTM)$211,600

Tangible BV / Share (Quarterly)$4.35

P/S Ratio (Annual)35.56x

Asset Turnover (Annual)0.09x

52-Week High$6.83

EPS Excl Extra (Annual)$-1.29

CapEx CAGR (5Y)-35.92%

26-Week Price Return200.93%

Quick Ratio (Annual)1.95x

13-Week Price Return49.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.03x

Enterprise Value$409.92M

Asset Turnover (TTM)0.14x

Book Value / Share Growth (5Y)-25.83%

Revenue / Employee (Annual)$153,700

Pretax Margin (Annual)-819.59%

Cash / Share (Annual)$1.64

3-Month Return Std Dev87.44%

Net Income / Employee (TTM)$-589,500

ROE (Last FY)-144.96%

EPS Basic Excl Extra (Annual)$-1.29

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.59

ROI (TTM)-74.57%

P/S Ratio (TTM)25.82x

Revenue / Share (Annual)$0.16

Tangible BV / Share (Annual)$4.08

Price vs S&P 500 (52W)403.46%

Year-to-Date Return123.10%

5-Day Price Return12.52%

EPS Normalized (Annual)$-1.29

ROA (5Y Avg)-55.14%

Net Profit Margin (Annual)-819.59%

Month-to-Date Return40.65%

Cash Flow / Share (TTM)$-2.12

EBITD / Share (Annual)$-1.34

Operating Margin (Annual)-861.33%

ROI (5Y Avg)-78.22%

EPS Basic Excl Extra (TTM)$-0.59

P/TBV (Quarterly)0.77x

P/B Ratio (Annual)2.39x

Pretax Margin (TTM)-278.51%

Book Value / Share (Annual)$1.09

Price vs S&P 500 (13W)46.63%

Beta0.93x

Revenue / Share (TTM)$0.20

ROE (TTM)-74.57%

52-Week Low$0.98

vGradeD

gGradeB

mGradeA

vgmGradeB

PRLD Earnings Surprise History

Q2 25-0.41est. -0.43

Q3 25-0.26est. -0.37

Q4 25-0.20est. -0.18

Q1 26-0.13est. -0.27

Q2 26-0.14est. -0.18

PRLD Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.22

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
PRLDPrelude Therapeutics Incorporated	D	B	A	$6.59
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Prelude Therapeutics Incorporated

Prelude Therapeutics is a clinical-stage precision oncology company developing small molecule therapies targeting key cancer driver mechanisms in high unmet need indications. The company's pipeline includes four candidates in clinical development: PRT1419 (MCL1 inhibitor), PRT2527 (CDK9 inhibitor), PRT3645 (next-generation CDK4/6 inhibitor), and PRT3789 (first-in-class SMARCA2/BRM protein degrader).